XML 102 R93.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 01, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 28, 2024
Jun. 12, 2024
Apr. 30, 2024
Mar. 31, 2024
Dec. 14, 2023
Dec. 06, 2023
May 31, 2023
Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]                          
Common stock, shares issued 55,766,078   56,091,677 55,766,078                  
Exercised number of shares     99,679                    
Stock-based compensation   $ 22,400 $ 48,070 $ 25,575 $ 27,316                
Stock options, outstanding 649,130   596,206 649,130                  
Restricted stock units, outstanding 474,320   470,612 474,320                  
Aggregate intrinsic value of stock options exercised     $ 10,400 $ 5,800 $ 14,100                
Weighted average grant date fair value of share-based awards granted     $ 88.00 $ 84.37 $ 87.40                
Total fair value of stock options vested     $ 7,800 $ 4,700 $ 3,100                
Weighted average grant date fair value of restricted stock units granted     $ 177.36                    
Total unrecognized compensation cost     $ 56,500                    
Unrecognized compensation cost, weighted average remaining requisite service period     2 years 8 months 12 days                    
Number of unvested options and restricted stock units     2,305,232                    
Forfeited portion of grants [1]     34,027                    
Share recalculated value             $ 136            
Avitide Llc                          
Stockholders Equity Note Disclosure [Line Items]                          
Common stock, shares issued               28,638       42,621  
Earnout consideration earned               50.00%       50.00%  
FlexBiosys, Inc.                          
Stockholders Equity Note Disclosure [Line Items]                          
Common stock, shares issued                 2,770        
Earnout consideration earned                 20.00%        
2018 Plan                          
Stockholders Equity Note Disclosure [Line Items]                          
Common stock shares reserved for Issuance                         2,778,000
Incentive options, vesting period 1,479,932     1,479,932                  
Common Stock                          
Stockholders Equity Note Disclosure [Line Items]                          
Repurchase of common stock (in shares)       (92,090)                  
Restricted Stock Units (RSUs)                          
Stockholders Equity Note Disclosure [Line Items]                          
Closing price of common stock           $ 143.94              
Unvested Options [Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Incentive options, vesting period     5 years                    
Restricted Stock And Performance Stock Units [Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Aggregate intrinsic value of restricted stock units vested     $ 26,700 $ 35,700 43,900                
Total grant date fair value of restricted stock units vested     22,000 $ 26,200 $ 22,700                
Two Thousand Twenty Four Grants [Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Stock-based compensation     $ 22,400                    
Forfeited portion of grants     32,776                    
Non Employee Director Stock Option[Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Estimated forfeiture rates     0.00%                    
Non-Executive [Member] | Employee Stock Option                          
Stockholders Equity Note Disclosure [Line Items]                          
Estimated forfeiture rates     8.00%                    
Non-Executive [Member] | Restricted Stock And Performance Stock Units [Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Estimated forfeiture rates     8.00%                    
Executive Officer [Member] | Employee Stock Option                          
Stockholders Equity Note Disclosure [Line Items]                          
Estimated forfeiture rates     3.00%                    
Executive Officer [Member] | Restricted Stock And Performance Stock Units [Member]                          
Stockholders Equity Note Disclosure [Line Items]                          
Estimated forfeiture rates     3.00%                    
1.00% Convertible Senior Notes due 2028                          
Stockholders Equity Note Disclosure [Line Items]                          
Net proceeds from public offering $ 14,400                        
Repurchase of common stock (in shares) 92,090                        
Closing price of common stock $ 156.22     $ 156.22             $ 156.2    
Share repurchase amount $ 25,000     $ 25,000                  
Aggregate principal amount $ 600,000     $ 600,000           $ 290,100      
1.00% Convertible Senior Notes due 2028 | Common Stock                          
Stockholders Equity Note Disclosure [Line Items]                          
Aggregate principal amount     $ 1,000                    
[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications.”